000128536 001__ 128536
000128536 005__ 20240228135105.0
000128536 0247_ $$2doi$$a10.1164/rccm.201309-1659OC
000128536 0247_ $$2pmid$$apmid:24564281
000128536 0247_ $$2ISSN$$a0003-0805
000128536 0247_ $$2ISSN$$a1073-449X
000128536 0247_ $$2ISSN$$a1535-4970
000128536 0247_ $$2altmetric$$aaltmetric:2150746
000128536 037__ $$aDKFZ-2017-04552
000128536 041__ $$aeng
000128536 082__ $$a610
000128536 1001_ $$0P:(DE-He78)40da88c1e07a6ce8bf1d138b6215471f$$aWielpütz, Mark Oliver$$b0$$eFirst author$$udkfz
000128536 245__ $$aMagnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease.
000128536 260__ $$aNew York, NY$$bAmerican Thoracic Society$$c2014
000128536 3367_ $$2DRIVER$$aarticle
000128536 3367_ $$2DataCite$$aOutput Types/Journal article
000128536 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522073148_4153
000128536 3367_ $$2BibTeX$$aARTICLE
000128536 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128536 3367_ $$00$$2EndNote$$aJournal Article
000128536 520__ $$aStudies demonstrating early structural lung damage in infants and preschool children with cystic fibrosis (CF) suggest that noninvasive monitoring will be important to identify patients who may benefit from early therapeutic intervention. Previous studies demonstrated that magnetic resonance imaging (MRI) detects structural and functional abnormalities in lungs from older patients with CF without radiation exposure.To evaluate the potential of MRI to detect abnormal lung structure and perfusion in infants and preschool children with CF, and to monitor the response to therapy for pulmonary exacerbation.MRI studies were performed in 50 children with CF (age, 3.1 ± 2.1 yr; range, 0-6 yr) in stable clinical condition (n = 40) or pulmonary exacerbation before and after antibiotic treatment (n = 10), and in 26 non-CF control subjects (age, 2.9 ± 1.9 yr). T1- and T2-weighted sequences before and after intravenous contrast and first-pass perfusion imaging were acquired, and assessed on the basis of a dedicated morphofunctional score.MRI demonstrated bronchial wall thickening/bronchiectasis, mucus plugging, and perfusion deficits from the first year of life in most stable patients with CF (global score, 10.0 ± 4.0), but not in non-CF control subjects (score, 0.0 ± 0.0; P < 0.001). In patients with exacerbations, the global MRI score was increased to 18.0 ± 2.0 (P < 0.001), and was significantly reduced to 12.0 ± 3.0 (P < 0.05) after antibiotic therapy.MRI detected abnormalities in lung structure and perfusion, and response to therapy for exacerbations in infants and preschool children with CF. These results support the development of MRI for noninvasive monitoring and as an end point in interventional trials for early CF lung disease. Clinical trial registered with www.clinicaltrials.gov (NCT00760071).
000128536 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000128536 588__ $$aDataset connected to CrossRef, PubMed,
000128536 7001_ $$aPuderbach, Michael$$b1
000128536 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b2$$udkfz
000128536 7001_ $$aStahl, Mirjam$$b3
000128536 7001_ $$aFritzsching, Eva$$b4
000128536 7001_ $$aSommerburg, Olaf$$b5
000128536 7001_ $$aLey, Sebastian$$b6
000128536 7001_ $$aSumkauskaite, Migle$$b7
000128536 7001_ $$0P:(DE-He78)09875ba4d79c705ab2086706cef963d5$$aBiederer, Jürgen$$b8$$udkfz
000128536 7001_ $$aKauczor, Hans-Ulrich$$b9
000128536 7001_ $$aEichinger, Monika$$b10
000128536 7001_ $$aMall, Marcus A$$b11
000128536 773__ $$0PERI:(DE-600)1468352-0$$a10.1164/rccm.201309-1659OC$$gVol. 189, no. 8, p. 956 - 965$$n8$$p956 - 965$$tAmerican journal of respiratory and critical care medicine$$v189$$x1535-4970$$y2014
000128536 909CO $$ooai:inrepo02.dkfz.de:128536$$pVDB
000128536 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)40da88c1e07a6ce8bf1d138b6215471f$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000128536 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000128536 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)09875ba4d79c705ab2086706cef963d5$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000128536 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000128536 9141_ $$y2014
000128536 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128536 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128536 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128536 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAM J RESP CRIT CARE : 2015
000128536 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128536 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128536 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128536 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128536 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128536 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128536 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128536 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bAM J RESP CRIT CARE : 2015
000128536 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x0
000128536 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000128536 980__ $$ajournal
000128536 980__ $$aVDB
000128536 980__ $$aI:(DE-He78)E010-20160331
000128536 980__ $$aI:(DE-He78)C060-20160331
000128536 980__ $$aUNRESTRICTED